Compare two analysis snapshots to see exactly what changed — new drugs, tier movements, pathway shifts. Use this for quarterly research reviews, internal documentation of hypothesis evolution, and tracking model drift across analysis runs.
| Drug Ranking Changes | |||
| ↑ | Encorafenib | Tier II → Tier I | +18 pts |
| = | Adagrasib | Tier I unchanged | — |
| ↓ | Temsirolimus | Tier I → Tier II | −12 pts |
| + | Tovorafenib | NEW — not in prior run | |
| − | Sorafenib | REMOVED — dropped below threshold | |
| Pathway Enrichment Changes | |||
| ↑ | MAPK/ERK signaling | FDR 0.003 → 0.0008 | stronger |
| + | PI3K/AKT pathway | NEW significance q < 0.05 | |
| Evidence Quality Trend | |||
| ↑ | Grounded ratio | 0% → 28% | improving |
| ↑ | Citation count | 6 → 12 papers | +6 |
| ↑ | Sources active | 28 → 31 databases | +3 |